OPPENHEIMER HOLDINGS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $OPY in the last 7 days.
No SEC Form 4 filings for $OPY in the last 30 days.
See all $OPY insider activity →Oppenheimer maintained a Buy rating on AutoZone (AZO) with a $3,500 price target. Morgan Stanley also has a Buy rating with a $3,605 target. AutoZone reported Q4 revenue of $4.84B and net profit of $641.49M, up from last year. Insider sentiment is negative, with recent share sales by executives.
Oppenheimer kept an Outperform rating on AutoZone with a $3500 price target, suggesting 23.1% upside from the Sep 17 close. The firm cites strategic investments to boost market share and a low forward PE multiple of 16x as reasons for the positive outlook.
Oppenheimer kept its Outperform rating on Amrize, setting a $55 price target, suggesting a 44% upside from the recent $38.19 close. The firm cited Amrize's strong market position in North American construction, particularly in data centers, and its growth prospects driven by capacity enhancements and M&A.
Recent OPY coverage spans financial news and earnings.
Oppenheimer maintained a Buy rating on AutoZone (AZO) with a $3,500 price target. Morgan Stanley also has a Buy rating with a $3,605 target. AutoZone reported Q4 revenue of $4.84B and net profit of $641.49M, up from last year. Insider sentiment is negative, with recent share sales by executives.
Oppenheimer kept an Outperform rating on AutoZone with a $3500 price target, suggesting 23.1% upside from the Sep 17 close. The firm cites strategic investments to boost market share and a low forward PE multiple of 16x as reasons for the positive outlook.
Oppenheimer kept its Outperform rating on Amrize, setting a $55 price target, suggesting a 44% upside from the recent $38.19 close. The firm cited Amrize's strong market position in North American construction, particularly in data centers, and its growth prospects driven by capacity enhancements and M&A.
Oppenheimer reduced its price target for AutoZone to $3,500 from $4,300, maintaining an outperform rating. The stock is currently trading at $2,850.50, down 16.13% year-to-date. UBS previously noted potential for fourth-quarter comps to miss street views due to soft aftermarket demand.
Oppenheimer increased its price target for Definium Therapeutics (DFTX) to $75 from $70, maintaining an Outperform rating. The firm cited positive Phase 3 trial results for DT120, which it believes support the company's potential to improve treatment for GAD patients. Oppenheimer updated its model to reflect increased optimism.
AlphAI scores every news story that mentions OPY with an AI model for sentiment and relevance, and aggregates insider trades from OPPENHEIMER HOLDINGS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Oppenheimer maintained a Buy rating on AutoZone (AZO) with a $3,500 price target. Morgan Stanley also has a Buy rating with a $3,605 target. AutoZone reported Q4 revenue of $4.84B and net profit of $641.49M, up from last year. Insider sentiment is negative, with recent share sales by executives.
1 min readOppenheimer kept an Outperform rating on AutoZone with a $3500 price target, suggesting 23.1% upside from the Sep 17 close. The firm cites strategic investments to boost market share and a low forward PE multiple of 16x as reasons for the positive outlook.
1 min readOppenheimer kept its Outperform rating on Amrize, setting a $55 price target, suggesting a 44% upside from the recent $38.19 close. The firm cited Amrize's strong market position in North American construction, particularly in data centers, and its growth prospects driven by capacity enhancements and M&A.
1 min readOppenheimer reduced its price target for AutoZone to $3,500 from $4,300, maintaining an outperform rating. The stock is currently trading at $2,850.50, down 16.13% year-to-date. UBS previously noted potential for fourth-quarter comps to miss street views due to soft aftermarket demand.
1 min readOppenheimer increased its price target for Definium Therapeutics (DFTX) to $75 from $70, maintaining an Outperform rating. The firm cited positive Phase 3 trial results for DT120, which it believes support the company's potential to improve treatment for GAD patients. Oppenheimer updated its model to reflect increased optimism.
1 min readSPCX stock rose 0.50% premarket after Oppenheimer raised its price target to $280, citing SpaceX's AI platform and higher revenue estimates. Oppenheimer maintained an 'outperform' rating, and other firms like Bernstein and JPMorgan also issued positive ratings. SpaceX's Q1 revenue grew 92% to $7.81B, with a net loss of $541M. The stock has gained over 30% in a month, trading at $142.97.
2 min readOppenheimer raised its price target for Palo Alto Networks to $450 from $400, maintaining an Outperform rating. The stock closed at $328.48, down 9.28% on the day.
1 min readOppenheimer maintained an Outperform rating on Amrize (NYSE: AMRZ) but lowered its price target to $65 from $68. Truist Securities downgraded Amrize to Hold with a $48 target, while Wells Fargo kept an Overweight rating but reduced its target to $58. Analysts show mixed views on the stock's near-term prospects.
2 min readDomino’s Pizza (DPZ) stock rose 5.4% following strong earnings and upbeat same-store sales growth. Analysts highlight its strong unit economics, with ROA above 30%, EBIT margin ~19%, and solid free cash flow. Oppenheimer maintains an outperform rating with a $415 target, citing quality growth and reasonable valuation at ~19.5x EPS. Technical analysis points to support near $332 and resistance at $355.
2 min readOppenheimer maintained an 'Outperform' rating for Elastic (ESTC) and raised its price target to $118 from $100. The company's stock is currently trading at $97.81, which is 7.0% below its GF Value™ of $105.18, suggesting it is undervalued. Elastic has a GF Score™ of 81/100, indicating strong overall performance, particularly in growth and valuation. Five gurus hold positions in ESTC, with four adding to their stakes recently.
2 min read
